Drug Database
Back to search

Belgium· BE-AMP-SAM663862-00

Gohibic 200 mg

A vilobelimab product containing vilobelimab, registered in Belgium by InflaRx. The same ATC class is registered in 8 of our 19 countries.

ATC L04AJ10

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedGohibic 200 mgATCL04AJ10REGISTER NO.BE-AMP-SAM663862-00PACKS LISTED0CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about vilobelimabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Vilobelimab is registered in 8 of 19 countries.

Countries holding a registration under ATC L04AJ10 (vilobelimab), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 5 of them publish a price we can compare per daily dose
Search vilobelimab products by name

Vilobelimab · ATC L04AJ10

8 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Vilobelimab
Manufacturer
InflaRx
Country
Belgium (BE)
ATC code
L04AJ10
ATC class
Vilobelimab
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Vilobelimab in 8 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All vilobelimab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Gohibic
  • Liechtenstein · Gohibic
  • Norway · Gohibic

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/00663c65-2deb-4527-8851-df5571798d80
GET /v1/drugs/00663c65-2deb-4527-8851-df5571798d80?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Concentrate for solution for infusion",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Gohibic 200 mg",
  "name_fr": "Gohibic 200 mg",
  "name_nl": "Gohibic 200 mg",
  "amp_code": "SAM663862-00",
  "strengths": [
    "10.0000",
    "10.0000",
    "74.2000"
  ],
  "pack_count": 1,
  "substances": [
    "Vilobelimab",
    "Polysorbate 80",
    "Sodium"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Vilobelimab",
  "authorisation_numbers": [
    "EU/1/24/1884/001"
  ]
}
API referenceMCP serverPlans

See everything about vilobelimab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console